Avoiding Statistical Pitfalls in Clinical Trials: Key Lessons for Biostatisticians

Introduction: The Cost of Statistical Missteps

Statistical analysis in clinical trials is a high-stakes responsibility. A single error in design, analysis, or interpretation can jeopardize not only the validity of the study but also patient safety, regulatory approval, and sponsor credibility. Regulatory authorities like the FDA and EMA increasingly scrutinize statistical methodology in New Drug Applications (NDAs) and Biologic License Applications (BLAs). For biostatisticians, this means that avoiding common mistakes isn’t just best practice—it’s essential compliance.

1. Misinterpreting P-Values

Perhaps the most prevalent misunderstanding in biostatistics is the misuse of p-values. Many professionals assume that a p-value < 0.05 guarantees the presence of a treatment effect. This oversimplification leads to erroneous conclusions.

• ❌ Mistake: Considering statistical significance synonymous with clinical relevance.
• ✅ Best Practice: Always pair p-values with effect sizes and confidence intervals. Use forest plots to visually communicate the uncertainty around estimates.

As emphasized in PharmaGMP’s case studies, regulators prefer holistic evaluation of efficacy, not p-hacking or cherry-picking results.

2. Failing to Check Assumptions of Statistical Tests

Parametric tests such as ANOVA, t-tests, or linear regression rely on assumptions—normal distribution, homogeneity of variance, and independence. Ignoring these assumptions can yield biased or invalid results.

Take for example a scenario where a t-test is applied without checking for normality:

✅ Solution: Conduct Shapiro–Wilk or Kolmogorov–Smirnov tests for normality. Use Levene’s or Bartlett’s test for variance equality. Document all diagnostic checks in the Statistical Analysis Plan (SAP).

3. Incorrect Sample Size Calculation

Underpowered studies may fail to detect true effects, while overpowered ones may inflate trivial differences. A poorly calculated sample size can derail ethical approval and financial planning.

Example: A Phase III study assumed a 30% treatment effect where the realistic expectation was 10%, leading to an underpowered trial and a regulatory rejection.

• ❌ Mistake: Overestimating expected treatment effect.
• ✅ Fix: Base calculations on historical data or pilot studies. Include a buffer for anticipated dropouts (commonly 10–20%).

Use validated tools like nQuery, PASS, or G*Power to cross-verify assumptions, and have the design peer-reviewed before protocol finalization.

4. Multiple Comparisons Without Adjustment

When multiple endpoints, subgroups, or timepoints are analyzed without statistical correction, the risk of false positives (Type I error) escalates dramatically. For example, testing 20 hypotheses at α=0.05 has a 64% chance of yielding at least one false positive.

❌ Error: Reporting all p-values without controlling the family-wise error rate.

✅ Solution: Use Bonferroni, Holm–Bonferroni, or False Discovery Rate (FDR) corrections. Clearly define primary and secondary endpoints in the protocol to limit exploratory analysis.

Regulators expect a predefined multiplicity strategy. Failure to adjust leads to Warning Letters, as highlighted in case reviews on ClinicalStudies.in.

5. Poor Handling of Missing Data

Missing data can bias results and violate assumptions of independence or randomization. Simply deleting records (listwise deletion) or using Last Observation Carried Forward (LOCF) without justification is frowned upon.

❌ Error: Using LOCF in progressive diseases like Alzheimer’s without regulatory justification.

✅ Best Practices:

• Imputation using multiple regression or MCMC algorithms.
• Conduct sensitivity analyses to compare imputation methods.
• Explain rationale in the SAP and Clinical Study Report (CSR).

6. Overfitting and Model Complexity

When biostatisticians include too many covariates relative to the number of observations, they risk overfitting. This means the model performs well on training data but poorly on unseen data.

Guideline: At least 10 events per covariate in logistic regression is a widely cited rule of thumb.

✅ Recommendation: Perform cross-validation and penalized regression (e.g., LASSO) when appropriate. Avoid over-interpreting models with R-squared > 0.90 unless justified.

Conclusion

Statistical integrity underpins the credibility of clinical research. Biostatisticians must move beyond rote use of software and embrace a disciplined, critical approach to design and analysis. Regulatory agencies have raised the bar—errors that once went unnoticed now face public scrutiny and lead to costly consequences.

By internalizing the best practices outlined here—from verifying assumptions and adjusting for multiplicity to improving documentation—you not only avoid statistical pitfalls but also become a valued scientific partner in clinical trials.

References:

• ICH E9 Guideline: Statistical Principles for Clinical Trials
• FDA Guidance on Multiple Endpoints in Clinical Trials
• WHO Handbook for Good Clinical Research Practice